Alpha-fetoprotein

Alpha-fetoprotein Informations sur la molécule

Nom anglais	Alpha-fetoprotein	Nombre de médicaments commercialisés	0
Nombre de médicaments cliniques	6	Alias de la cible	Alpha-Fetoglobulin，AFP，Alpha-fetoprotein，Alpha Fetoprotein，Alpha-1-Fetoprotein，HPAFP，AFPD，FETA，alpha-Fetoproteins
Phase de R&D la plus avancée	Phase 2 Clinical

Nom anglais	Alpha-fetoprotein
Alias de la cible	Alpha-Fetoglobulin，AFP，Alpha-fetoprotein，Alpha Fetoprotein，Alpha-1-Fetoprotein，HPAFP，AFPD，FETA，alpha-Fetoproteins
Nombre de médicaments commercialisés	0
Nombre de médicaments cliniques	6
Phase de R&D la plus avancée	Phase 2 Clinical

Alpha-fetoprotein Liste de produits

Attribut
Protein (1)
Bibliothèque de produits
En ligne (1)
Espèces
Human (1)
Étiquette
His Tag (1)
Marqueur
Unconjugated (1)

Numéro de produit	Espèces	Système d'expression	Description du produit	Structure protéique	Pureté	Caractéristiques	Pré-commande/Commande
ALN-H52H9	Human	HEK293	Human Alpha-fetoprotein, His Tag (MALS verified)				Ajouter au panier

Quantité totale1

Alpha-fetoproteinContexte de la molécule

Alpha-fetoprotein(AFP) is the first tumor marker with clinical application value found by human. AFP has an ability to induce the immune escapes through inhibiting the function of dendritic cells, natural killer cells, and T lymphocytes. By in vitro modification, the immunogenicity and immune response of AFP could be enhanced. AFP-modified immune cell vaccine or peptide vaccine has displayed the specific antitumor immunity against AFP-positive tumor cells and laid a better foundation for the immunotherapy of liver cancer. Alpha-fetoprotein is found in monomeric as well as dimeric and trimeric forms, and binds copper, nickel, fatty acids and bilirubin. The level of alpha-fetoprotein in amniotic fluid is used to measure renal loss of protein to screen for spina bifida and anencephaly.

Alpha-fetoproteinAlias de la molécule

Alpha-fetoprotein

Informations sur les médicaments cliniques

Nom anglais	Code de recherche	Phase de R&D	Entreprise	Indication	Essai clinique
TAEST-1901	TAEST-1901	Phase 2 Clinical	Xiangxue Life Science Technology (Guangdong) Co Ltd	Liver Neoplasms; Neoplasms; Solid tumours; Stomach Neoplasms	Details
JWATM-203	JWATM-203; JWATM203	Phase 2 Clinical	Suzhou Yaomingjunuo Biotechnology Co Ltd	Carcinoma, Hepatocellular	Details
SynOV1.1	SynOV1.1	Phase 2 Clinical	Beijing Syngentech Co Ltd	Carcinoma, Hepatocellular; Solid tumours	Details
ET140203		Phase 2 Clinical	Eureka Therapeutics Inc	Carcinoma, Hepatocellular; Hepatoblastoma; Liver Neoplasms	Details
CPU-118	CPU-118	Phase 2 Clinical	China Pharmaceutical University, Nanjing Qinling Pharmaceutical Technology Co Ltd	Liver Neoplasms; Neoplasms; Solid tumours	Details
Alpha fetoprotein targeted T-cell therapy (Adaptimmune)	AFP TCR (ADP-A2AFP); ADP-A2AFP; AFP TCR; AFPc332T	Phase 1 Clinical	Adaptimmune Llc	Carcinoma, Hepatocellular	Details